Endothelial-mediated microcirculatory responses to an acute estradiol test are influenced by time since menopause, cumulative hormone exposure, and vasomotor symptoms

Menopause

Volumn 17, Issue 4, 2010, Pages 749-757

  Clapauch, Ruth ^a,b   Mecenas, Anete S ^a   Maranhão, Priscila A ^a   Bouskela, Eliete ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b HOSPITAL DA LAGOA   (Brazil)

Author keywords

Cardiovascular; Endothelial; Estradiol; Menopause; Time since menopause; Vasomotor symptoms

Indexed keywords

ESTRADIOL; TRIACYLGLYCEROL; ESTROGEN; ORAL CONTRACEPTIVE AGENT;

ADULT; AGED; ARTICLE; CAPILLAROSCOPY; CIGARETTE SMOKING; ENDOTHELIUM; ERYTHROCYTE KINETICS; FEMALE; HUMAN; MICROCIRCULATION; NORMAL HUMAN; POSTMENOPAUSE; TRIACYLGLYCEROL BLOOD LEVEL; VASOMOTOR DISORDER; BLOOD; BLOOD FLOW VELOCITY; ERYTHROCYTE; HORMONE SUBSTITUTION; HOT FLUSH; INTRANASAL DRUG ADMINISTRATION; MENOPAUSE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; SMOKING; TIME; VASCULAR ENDOTHELIUM; VASODILATATION; VIDEO MICROSCOPY;

ADMINISTRATION, INTRANASAL; ADULT; AGED; BLOOD FLOW VELOCITY; CONTRACEPTIVES, ORAL; ENDOTHELIUM, VASCULAR; ERYTHROCYTES; ESTRADIOL; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HOT FLASHES; HUMANS; MENOPAUSE; MICROCIRCULATION; MICROSCOPY, VIDEO; MIDDLE AGED; SMOKING; TIME FACTORS; TRIGLYCERIDES; VASODILATION;

EID: 77954954420     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181cde2bd     Document Type: Article

References (60)

1. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med 1976;85:447-452.
2. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-1811.
3. Grodstein F, Manson JE, Stampfer MJ. Postmenopausal hormone use and secondary prevention of coronary events in the Nurses' Health Study. A prospective, observational study. Ann Intern Med 2001;135:1-8.
4. Prelevic GM, Kwong P, Byrne DJ, Jagroop IA, Ginsburg J, Mikhailidis DP. A cross-sectional study of the effects of hormone replacement therapy on cardiovascular disease risk profile in healthy postmenopausal women. Fertil Steril 2002;77:945-951.
5. Lobo RA. Evaluation of cardiovascular event rates with hormone ther-apy in healthy, early postmenopausal women: results from 2 large clin-ical trials. Arch Intern Med 2004;164:482-484.
6. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49-57. (Pubitemid 34705518)
7. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
8. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
9. Koledova VV, Khalil RA. Sex hormone replacement therapy and mod-ulation of vascular function in cardiovascular disease. Expert Rev Cardiovasc Ther 2007;5:777Y789.
10. Rosano GMC, Panina G. Cardiovascular pharmacology of hormone replacement therapy. Drugs Aging 1999;15:219-234.
11. Wang J, Widlansky ME. Lifestyle choices and endothelial function: risk and relevance. Curr Vasc Pharmacol 2009;7:209-224.
12. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation 2005;111:363-368.
13. Clarkson TB, Appt SE. Controversies about HRTVlessons from monkey models. Maturitas 2005;51:64-74.
14. Hanke H, Kamenz J, Hanke S, et al. Effect of 17-A estradiol on pre-existing atherosclerotic lesions: role of the endothelium. Atherosclerosis 1999;147:123-132.
15. Holm P, Andersen HL, Andersen MR, Erhardtsen E, Stender S. The direct antiatherogenic effect of estrogen is present, absent, or reversed, depending on the state of the arterial endothelium. A time course study in cholesterol-clamped rabbits. Circulation 1999;100:1727-1733.
16. Villela NR, Kramer-Aguiar LG, Bottino DA, Wiernsperger N, Bouskela E. Metabolic disturbances linked to obesity: the role of im-paired tissue perfusion. Arq Bras Endocrinol Metabol 2009;53:238-245.
17. Fagrell B, Intaglietta M. The dynamics of skin microcirculation as a tool for the study of systemic diseases. Bibl Anat 1977;16:231-234.
18. Fagrell B, Fronek A, Intaglietta M. A microscope television system for studying flow velocity in human skin capillaries. Am J Physiol 1977; 233:H318-H321.
19. Kraemer-Aguiar LG, Laflor CM, Bouskela E. Skin microcirculatory dysfunction is already present in normoglycemic subjects with metabolic syndrome. Metabolism 2008;57:1740-1746.
20. Ostergren J, Fagrell B. Skin capillary blood cell velocity in man. Char-acteristics and reproducibility of the reactive hyperemia response. Int J Microcirc Clin Exp 1986;5:37-51.
21. Clapauch R, Mecenas AS, Maranhão PA, Bouskela E. Microcirculatory function in postmenopausal women: role of aging, hormonal exposure and metabolic syndrome. Microvasc Res 2009;78:405-412.
22. Clarkson TB. Can women be identified that will derive considerable cardiovascular benefits from postmenopausal estrogen therapy? J Clin Endocrinol Metab 2008;93:37-39.
23. Gavin KM, Seals DR, Silver AE, Moreau KL. Vascular endothelial estrogen receptor α is modulated by estrogen status and related to endo-thelial function and endothelial nitric oxide synthase in healthy women. J Clin Endocrinol Metab 2009;94:3513-3520.
24. Kim KH, Moriarty K, Bender JR. Vascular cell signaling by membrane estrogen receptors. Steroids 2008;73:864-869.
25. Leung SW, Teoh H, Keung W, Man RY. Non-genomic vascular actions of female sex hormones: physiological implications and signalling pathways. Clin Exp Pharmacol Physiol 2007;34:822-826.
26. Dooley M, Spencer CM, Ormrod D. Estradiol-intranasal: a review of its use in the management of menopause. Drugs 2001;61:2243-2262. (Pubitemid 34074807)
27. Simoncini T, Fornari L, Mannella P, et al. Differential estrogen signaling in endothelial cells upon pulsed or continuous administration. Maturitas 2005;50:247-258.
28. Stefano GB, Prevot V, Beauvillain JC, et al. Estradiol coupling to human monocyte nitric oxide release is dependent on intracellular cal-cium transients: evidence for an estrogen surface receptor. J Immunol 1999;163:3758-3763.
29. Simoncini T, Mannella P, Genazzani AR. Rapid estrogen actions in the cardiovascular system. Ann N Y Acad Sci 2006;1089:424-430.
30. Dancour MA, Vaz JL, Bottino DA, Bouskela E. Nailfold videocapillaro-scopy in patients with systemic lupus erythematosus. Rheumatol Int 2006; 26:633-637.
31. Klyscz T, Jünger M, Jung F, Zeintl H. Cap imageVein neuartiges computerunterstütztes videoanalysesystem für die dynamische kapillar-mikroskopie. Biomed Tech 1997;42:168-175.
32. Wygoda MM, Filippo RB Jr, Gomes MAS, Clapauch R. Monitorizando a terapia de reposi0ão estrogênica (TRE) na menopausa. Arq Bras Endocrinol Metab 1999;43:336-343.
33. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-1847.
34. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and A-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
35. Volterrani M, Rosano G, Coats A, Beale C, Collins P. Estrogen acutely increases peripheral blood flow in postmenopausal women. Am J Med 1995;99:119-122.
36. Vitale C, Mercuro G, Cerquetani E, et al. Time since menopause in-fluences the acute and chronic effect of estrogens on endothelial func-tion. Arterioscler Thromb Vasc Biol 2008;28:348-352.
37. Haenggi W, Linder HR, Birkhaeuser MH, Schneider H. Microscopic findings of the nail-fold capillariesVdependence on menopausal status and hormone replacement therapy. Maturitas 1995;22:37-46.
38. Brownley KA, Hinderliter AL, West SG, et al. Cardiovascular effects of 6 months of hormone replacement therapy versus placebo: differences associated with years since menopause. Am J Obstet Gynecol 2004;190: 1052-1058.
39. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since men-opause. JAMA 2007;297:1465-1477.
40. Salpeter SR, Walsh JM, Greyber E, Salpeter EE. Brief report: coronary heart disease events associated with hormone therapy in younger and older women: a meta-analysis. J Gen Intern Med 2006;21:363-366.
41. Post WS, Goldschmidt-Clermont PJ, Wilhide CC, et al. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovasc Res 1999;43:985-991.
42. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health 2006;15:35-44. (Pubitemid 43192860)
43. Hodis HN. Assessing benefits and risks of hormone therapy in 2008: new evidence, especially with regard to the heart. Cleve Clin J Med 2008;75:S3-S12.
44. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006;166:357-365. (Pubitemid 43244325)
45. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534.
46. Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007;356:2591-2602.
47. Karim R, Mack WJ, Lobo RA, et al. Determinants of the effect of estrogen on the progression of subclinical atherosclerosis: Estrogen in the Prevention of Atherosclerosis Trial. Menopause 2005;12:366-373.
48. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008; 107:103-111.
49. Cherney DZ, Scholey JW, Cattran DC, et al. The effect of oral con-traceptives on the nitric oxide system and renal function. Am J Physiol Renal Physiol 2007;293:F1539-F1544.
50. Wiernsperger N, Nivoit P, De Aguiar LG, Bouskela E. Microcirculation and the metabolic syndrome. Microcirculation 2007;14:403-438.
51. Vasques AC, Rosado LEFPL, Alfenas RDCG, Geloneze B. Critical analysis on the use of the homeostasis model assessment (HOMA) indexes in the evaluation of the insulin resistance and the pancreatic beta cells functional capacity. Arq Bras Endocrinol Metab 2008;52:32-39.
52. Lundman P, Eriksson M, Schenck-Gustafsson K, Karpe F, Tornvall P. Transient triglyceridemia decreases vascular reactivity in young, healthy men without risk factors for coronary heart disease. Circulation 1997; 96:3266-3268.
53. Martin KA, Manson JE. Approach to the patient with menopausal symptoms. J Clin Endocrinol Metab 2008;93:4567-4575.
54. Kronenberg F, Cote LJ, Linkie DM, Dyrenfurther I, Downey JA. Menopausal hot flashes: thermoregulatory, cardiovascular and circulat-ing catecholamine and LH changes. Maturitas 1984;6:31-43.
55. Thurston RC, Sowers MR, Sutton-Tyrrell K, et al. Abdominal adiposity and hot flashes among midlife women. Menopause 2006;15:429-434.
56. Thurston RC, Sutton-Tyrrell K, Everson-Rose SA, Hess R, Matthews KA. Hot flashes and subclinical cardiovascular disease: findings from the Study of Women's Health Across the Nation Heart Study. Circulation 2008;118:1234-1240.
57. Tuomikoski P, Ebert P, Groop PH, et al. Evidence for a role of hot flushes in vascular function in recently postmenopausal women. Obstet Gynecol 2009;113:902-908.
58. Binder S, Navratil K, Halek J. Chronic smoking and its effect on arterial stiffness. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008;152:299-302.
59. Zimlichman R, Boaz M, Duprez D, et al. Effects of moderate smok-ing on arterial elasticityin healthy European populationV the seven European sites study of arterial elasticity. Am J Hypertens 2003;16: A149-A150.
60. Kim JW, Park CG, Hong SJ, et al. Acute and chronic effects of cigarette smoking on arterial stiffness. Blood Press 2005;14:80-85.